Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 known ✓ | P34969 | 18/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 6/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | HTR5A known ✓ | P47898 | 2/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.98 |
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 0.98 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.98 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.98 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.73 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.67 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.67 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2719588 | 1.00 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| SCHEMBL375474 | 0.99 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| SCHEMBL375475 | 0.99 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| Sb-258741 SCHEMBL4454954 | 0.87 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| Sb-258741 SCHEMBL4459020 | 0.87 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| Hydrochloric Acid SCHEMBL14893193 | 0.87 | HTR7 (0.77) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| SCHEMBL4298542 | 0.86 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| SCHEMBL4298546 | 0.86 | HTR7 (1.00) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| SCHEMBL5809435 | 0.86 | HTR7 (0.78) | HTR7HTR1BDRD3HTR5ATMEM97 | |
| SCHEMBL14117920 | 0.85 | HTR7 (0.77) | HTR7HTR1BDRD3HTR5ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | claimed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | claimed |
| US-20170196908-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY | 2017-07-13 | — | — | US | claimed |
| EP-3151818-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | Case Western Reserve University (US) | 2017-04-12 | — | — | EP | claimed |
| WO-2015187942-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-12-10 | — | — | WO | claimed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | claimed |
| US-20130287705-A1 | METHOD OF TREATING MUCOSAL INFLAMMATION | MCMASTER UNIVERSITY (CA) | 2013-10-31 | — | — | US | claimed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2012058769-A1 | METHOD OF TREATING MUCOSAL INFLAMMATION | MCMASTER UNIVERSITY (CA) | 2012-05-10 | — | — | WO | claimed |
| CN-110475773-B | 8-Phenylisoquinoline and pharmaceutical composition thereof for treating irritable bowel syndrome | 琳达·佳慧·余 | 2025-06-24 | — | — | CN | disclosed |
| EP-3589626-B1 | 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME | UNIV NAT TAIWAN (TW) | 2024-06-12 | — | — | EP | disclosed |
| US-20240093148-A1 | METHOD FOR DIFFERENTIATING HUMAN INDUCED PLURIPOTENT STEM CELLS INTO OLIGODENDROCYTES, AND KIT AND USE | ALLIFE MEDICINE (ZHUHAI) LIMITED (CN) | 2024-03-21 | — | — | US | disclosed |
| US-11505529-B2 | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome | NATIONAL TAIWAN UNIVERSITY (TW) | 2022-11-22 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-20130287705-A1 | METHOD OF TREATING MUCOSAL INFLAMMATION | MCMASTER UNIVERSITY (CA) | 2013-10-31 | — | — | US | disclosed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012058769-A1 | METHOD OF TREATING MUCOSAL INFLAMMATION | MCMASTER UNIVERSITY (CA) | 2012-05-10 | — | — | WO | disclosed |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | HTR7 3012/4885HTR1B 3415/4885DRD3 4353/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | HTR7 897/4885HTR1B 1116/4885DRD3 1472/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | HTR7 897/4885HTR1B 1116/4885DRD3 1472/4885 |
| US-11505529-B2 | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome | HTR7, GPR27, HTR5A | HTR7 1/4885HTR1B 39/4885DRD3 579/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | HTR7 3012/4885HTR1B 3415/4885DRD3 4353/4885 |
| US-20170196908-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | HTR7 897/4885HTR1B 1116/4885DRD3 1472/4885 |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | HTR7, HTR1A, HTR6 | HTR7 1/4885HTR1B 11/4885DRD3 183/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | HTR7 897/4885HTR1B 1116/4885DRD3 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.